A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib

Newton A. C. S. Wong (Lead / Corresponding author), Christel Garcia-Petit, Adam Dangoor, Nicola Andrew

Research output: Contribution to journalArticlepeer-review

Abstract

It is well recognized that the primary KIT or PDGFRA variant of a gastrointestinal stromal tumour (GIST) can predict sensitivity to imatinib. However, these data are currently spread across a wide range of publications and have not been collated as one reference. A broad-ranging literature search was therefore performed to assemble such a database which should help optimize imatinib-based management of GIST patients henceforth. Having excluded wild type GISTs and results for imatinib used as adjuvant therapy, 79 publications (dated August 2001 to March 2022) underwent data extraction. These data on imatinib sensitivity were either derived from in vitro studies, predicted by in silico analysis or based on in vivo clinical patient response. Data interpretation carried some caveats: there was a potential for replication of patient-derived data between older and new publications; only predicted protein sequences were presented; the criteria used to record clinical response were not uniform across all publications; and imatinib dosage could vary between different clinical publications. However, these data showed broad agreement of imatinib sensitivity amongst similar subtypes of KIT or PDGFRA variant. There was also agreement between in vivo versus in vitro/in silico derived sensitivity data for most variants when both data types were available.

Original languageEnglish
Pages (from-to)46-54
Number of pages9
JournalCancer Genetics
Volume268-269
Early online date8 Sep 2022
DOIs
Publication statusPublished - 1 Nov 2022

Keywords

  • Gastrointestinal stromal tumour
  • Imatinib
  • KIT
  • PDGFRA
  • Sensitivity

Fingerprint

Dive into the research topics of 'A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib'. Together they form a unique fingerprint.

Cite this